Accenture: New R&D IT infrastructure, new acronym

Accenture perceives an ominous road for biopharma R&D. Successful companies will transition to an informatics-reliant R&D model, one born of evolutionary and revolutionary changes to current discovery and development methods. This future model requires an IT infrastructure that is secure yet elastic, integrating data from existing sources as well as new ones like sentiment monitoring and social networks. And to underscore the change, a new acronym: D2i, for "data to insights: the ability to convert data into decision-making, product-shaping, market/customer-influencing insights." Article

Suggested Articles

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.

TriNetX's platform uses EHR data to help drug developers with clinical trial protocol design and study site and participant identification.

The $58 million financing round represents biopharma industry's growing interest in genomics data.